Sugi Predict

Sugi Predict / Compounds / SCHEMBL2890715

SCHEMBL2890715

SCHEMBL2890715

O=C1CNCC2CCCN12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 2/20 0.44
▸ NOS3 P29474 1/20 0.44
▸ MEN1 O00255 3/20 0.39
▸ GAA P10253 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ HTR6 P50406 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ HTR2C P28335 3/20 0.32
▸ HTR2B P41595 3/20 0.32
▸ HTR2A P28223 2/20 0.32
▸ PARP1 P09874 1/20 0.31
▸ CHRNB2 P17787 1/20 0.30
▸ CHRNB4 P30926 1/20 0.30
▸ CHRNA3 P32297 1/20 0.30
▸ CHRNA7 P36544 1/20 0.30
▸ CHRNA4 P43681 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL337898 1.00 NOS1 (0.44) NOS1NOS3MEN1GAAKMT2A
SCHEMBL337466 1.00 NOS1 (0.44) NOS1NOS3MEN1GAAKMT2A
Hydrochloric Acid SCHEMBL16967078 0.98 NOS1 (0.42) NOS1NOS3MEN1GAAKMT2A
Hydrochloric Acid SCHEMBL16967077 0.98 NOS1 (0.42) NOS1NOS3MEN1GAAKMT2A
SCHEMBL3087078 0.94 HTR6 (0.41) NOS1NOS3MEN1GAAKMT2A
SCHEMBL3080507 0.94 HTR6 (0.41) NOS1NOS3MEN1GAAKMT2A
SCHEMBL18689264 0.94 HTR6 (0.41) NOS1NOS3MEN1GAAKMT2A
SCHEMBL24087197 0.92 HTR6 (0.40) NOS1NOS3MEN1GAAKMT2A
SCHEMBL21946138 0.92 HTR6 (0.40) NOS1NOS3MEN1GAAKMT2A
SCHEMBL12342202 0.88 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115996927-A Pyrimido [5,4-d ] pyrimidine derivatives and combinations with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer ITEOS比利时公司 2023-04-21 — — CN claimed
CN-110382499-B FGFR inhibitor and application thereof 贝达药业股份有限公司 2023-01-03 — — CN claimed
CN-116249701-B Substituted di (pyridin-2-yl) amine derivatives, compositions and pharmaceutical uses thereof 上海海雁医药科技有限公司 2025-05-30 — — CN disclosed
CN-119768404-A Heteroaryl substituted pyridopyrrolidone derivatives, pharmaceutical compositions and uses thereof 上海海雁医药科技有限公司 2025-04-04 — — CN disclosed
CN-115703765-B Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof 上海赛默罗生物科技有限公司 2025-02-28 — — CN disclosed
CN-118373808-A Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof 上海海雁医药科技有限公司 2024-07-23 — — CN disclosed
CN-113748110-B Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof 上海海雁医药科技有限公司 2024-05-14 — — CN disclosed
EP-3632907-B1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-02-28 — — EP disclosed
EP-3663285-B1 FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-01-24 — — EP disclosed
EP-3632906-B1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY ABBISKO THERAPEUTICS CO LTD (CN) 2023-12-13 — — EP disclosed
EP-4282868-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE DERIVATIVE, AND COMPOSITIONS AND MEDICAL USE THEREOF Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) 2023-11-29 — — EP disclosed
EP-1425029-A4 PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES PALATIN TECHNOLOGIES INC (US) 2006-06-07 — — EP disclosed
WO-2005079574-A1 BICYCLIC MELANOCORIN-SPECIFIC COMPOUNDS PALATIN TECHNOLOGIES, INC. (US) 2005-09-01 — — WO disclosed
US-20040171520-A1 Peptidomimetics of biologically active metallopeptides PALATIN TECHNOLOGIES, INC. 2004-09-02 — — US disclosed
US-20040152134-A1 Bicyclic melanocortin-specific compounds PALATIN TECHNOLOGIES, INC. (US) 2004-08-05 — — US disclosed
US-6750344-B1 MONOCYCLIC AMINE SCAFFOLD BEARING AT LEAST TWO SITES OF DIVERSITY, CYCLIZED TO FORM BICYCLIC AMINE SCAFFOLDS; 7-AMINO-PYRROLO(1,2-A)PYRAZIN-4-ONE COMPOUNDS ISIS PHARMACEUTICALS, INC. 2004-06-15 — — US disclosed
EP-1425029-A1 PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES Palatin Technologies, Inc. (US) 2004-06-09 — — EP disclosed
WO-2003013571-A1 PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES PALATIN TECHNOLOGIES, INC. (US) 2003-02-20 — — WO disclosed
US-6316626-B1 Amine compounds and combinatorial libraries comprising same ISIS PHARMACEUTICALS, INC. 2001-11-13 — — US disclosed
WO-1999012034-A1 AMINE COMPOUNDS AND COMBINATORIAL LIBRARIES COMPRISING SAME ISIS PHARMACEUTICALS, INC. (US) 1999-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171520-A1 Peptidomimetics of biologically active metallopeptides MC1R, MC4R, MC5R NOS1 2796/4885NOS3 2375/4885MEN1 76/4885
US-20040152134-A1 Bicyclic melanocortin-specific compounds MC3R, MC5R, MC2R NOS1 4812/4885NOS3 4531/4885MEN1 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.